Published 2026-06-16
The ECB’s first rate increase since the inflation resurgence faces a still-cautious Federal Reserve and fragile credit conditions, setting a tense backdrop for the heavy central-bank calendar ahead.
At a glance
This weekECB Becomes First Major Central Bank to Raise Interest Rates Since Inflation Resurgence
Model stance70% cash · 17 positions
Track record44% hit rate (n=43)
Recent Events
The ECB became the first major central bank to raise rates since the inflation resurgence, a historic move that followed its June 4th policy meeting and landed just a day after the US CPI release. Federal Reserve communication stayed exceptionally subdued, scoring only 10 and then 15 on a 100‑point tone scale, even as a nominee to succeed the Fed chair was named. Corporate buyback programmes expanded to 7,750 active plans with a trailing twelve‑month total of $65.2 trillion, but credit conditions looked far less buoyant: the average survival gauge held at 40 out of 100, with 28 companies flagged in danger and high‑yield spreads flat. Single‑name news ranged from a pair of FDA Class I device recalls to Enliven Therapeutics’ updated Phase 1 data and Broadcom’s quarterly results, leaving the market to weigh that policy milestone against still‑nervous credit signals.
Macro & policy
2026-06-11ECB Becomes First Major Central Bank to Raise Interest Rates Since Inflation Resurgence
2026-06-11Fed Communication: 15/100 (LOW)
2026-06-04Fed Communication: 10/100 (LOW)
2026-06-04Fed chair succession: nominee named
Credit & corporate
2026-06-11Buybacks: 7750 active, $65221B TTM
2026-06-11Credit survival: avg 40/100, 28 in danger
2026-06-11HY OAS Weekly: FLAT → hold cash
2026-06-04Buybacks: 7734 active, $64959B TTM
On the calendar
2026-06-10Consumer Price Index (CPI) release
2026-06-04ECB Governing Council monetary policy meeting
Notable news
2026-06-10BDX (Becton Dickinson & Company)
2026-06-10B Braun Medical Inc
2026-06-16Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
2026-06-16Broadcom Inc.
Upcoming Events
A heavy cluster of central-bank decisions anchors the calendar, with the FOMC and the Bank of Japan both concluding meetings on the same day, followed hours later by the Bank of England’s policy announcement. That concentrated macro risk lands immediately before the quarterly triple-witching expiration, a regular liquidity event that can amplify repositioning flows. Beyond June, the data diet stays rich: the Fed’s preferred inflation gauge and first-quarter GDP arrive together, then the July payrolls report gives way to a back-to-back CPI and PPI release. Meanwhile, a potential fast-entry window for SpaceX into the Nasdaq-100 in early July sits on the horizon as a wildcard for index-repricing and liquidity draw, and a growing earnings calendar—with early reads from MAMA, SWBI, and LZB—fills out the backdrop.
2026-06-17● FOMC monetary policy decision (US)
2026-06-17● Bank of Japan Monetary Policy Meeting (JP)
2026-06-18● Bank of England MPC monetary policy decision (UK)
2026-06-18● Triple witching (quarterly options & futures expiration) (US)
2026-06-22● PBOC Loan Prime Rate (LPR) fixing (CN)
2026-06-25● Personal Income & Outlays (PCE) release (US)
2026-06-25● Gross Domestic Product (GDP) release (US)
2026-07-02● Employment Situation (Nonfarm Payrolls) release (US)
2026-07-06● SpaceX Nasdaq-100 fast-entry window (US)
2026-07-14● Consumer Price Index (CPI) release (US)
2026-07-15● Producer Price Index (PPI) release (US)
Plus 99 corporate earnings reports scheduled in the window.
Macro Projections
The near-term outlook leans improving, as the US-Iran peace deal removes a potential oil‑shock tail and markets price a risk‑on backdrop of low VIX and tight credit, though a Bank of Japan rate increase and the Federal Reserve’s upcoming decision create cross‑currents that keep the yen weak above 160 to the dollar. Confidence in that tactical improvement is only moderate: the FOMC and BOJ decisions on 17 June 2026, together with the quarterly triple‑witching expiration of equity derivatives, could jolt volatility sharply, making forecasts fragile around policy events. Stepping back to a cyclical horizon of months to quarters, the picture shifts to range‑bound with low confidence, as the credit cycle remains early—high‑yield spreads are tightening but the widening gap between CCC‑ and BB‑rated debt and elevated core inflation keep recession risk alive. Here, real assets are expected to outperform as the financial‑repression narrative gains traction, but the regime has not yet definitively flipped, leaving the trajectory sensitive to the inflation path and the Fed’s reaction. On a secular, multi‑year timeframe, however, the direction is deteriorating with higher confidence, driven by a structural shift toward financial repression, fiscal dominance, and de‑dollarization. That shift is raising the term premium, structurally impairing nominal bonds and long‑duration growth equities, while real assets—gold, inflation‑protected bonds, energy, and select international markets—gain a structural advantage. The near‑term risk‑on bias therefore runs against a deeper current: a fragile policy juncture sits atop a credit cycle yet to fully resolve, which itself unfolds inside a long arc that steadily favors real over nominal exposures, even though the magnitude and timing of that secular transition remain uncertain.
Near term ▬●●● expires Jul 16, 2026
The FOMC holds rates steady, and the CBOE Volatility Index (VIX) remains below 20 over the next 30 days.
Cross-validated macro and crowd pricing. The Fed model’s hold propensity is 0.838 with a stable intervention propensity trajectory (0.165).
Cyclical ▼●●● expires Sep 14, 2026
The CCC-BB credit spread divergence accelerates, pushing the ICE BofA US High Yield OAS above 3.25%.
Trajectory-based credit read. The ccc_bb_z36_traj is at 2.4382 and accelerating positive, indicating a persistent trend of bottom-spread widening.
Secular ▲●●● expires Jun 16, 2027
Developed market equities ex-US (earnings yield 5.37%) will outperform US equities (implied 10-year real return 2.41%) over the next 12 months.
Cross-domain valuation argument. The US CAPE ratio sits at an extreme 41.4, while narrative edges confirm central banks are actively diversifying reserves away from the USD and into gold.
Near term ▲●●● expires Jul 16, 2026
The VIX spikes above 25 and the MOVE index returns above 85 basis points during the June 17-18 central bank decisions.
Event-driven cross-asset vol read. The VIX term structure is deeply backwardated at 0.862 (direction: accelerating negative), and the vol of vol (VVIX) is at 87.58.
Cyclical ▲●●● expires Sep 14, 2026
The Caldara-Iacoviello Geopolitical Risk (GPR) index falls below 150 and Brent crude oil prices remain under pressure below $80/bbl.
Primary-source geopolitical catalyst. WSJ news clips confirm an interim peace deal to reopen the Strait of Hormuz, directly addressing the "iran_hormuz near closure" crisis.
Positioning
A calm credit regime, with high-yield spreads near 2.71%, keeps the model on a steady footing. Every position weight scales to conviction: the screening-kernel composite score blends expected three-month upside drift against drawdown probability, so the highest-scoring names naturally command the largest equity allocations. The three strongest marks in the book—PHAT, TER, and NEM, each with a composite near 4.4 and modelled upside in the 4.7–5.0% range—set the core risk appetite. Around that, three structural mechanisms (oil supply shocks, commodity production losses, and yen carry unwind risk-off) enter the weighting calculus as honest inputs, each measured by its own hit rate and trimmed for what the market already prices.
| Name | Conviction score | Modelled drift |
|---|
| PHAT | 4.44 | +4.9% |
| TER | 4.43 | +4.7% |
| NEM | 4.40 | +5.0% |
| AENT | 4.29 | +4.5% |
| TSM | 4.07 | +4.7% |
| INOD | 3.99 | +4.6% |
oil supply shock headline cpi → headline CPI ▲ · 86% base rate · n=7 · 60% pricedcommodity production loss → agricultural commodity ▲ · 80% base rate · n=5 · 40% pricedyen carry unwind risk off → global equities ▼ · 55% base rate · n=38 · 20% priced
Model Portfolio
The model portfolio holds back a substantial cash position as dry powder, ready to deploy in stages as credit and volatility conditions evolve. The deployed capital is concentrated across a few deliberate structural sleeves: inflation-linked real-yield exposure anchored to the financial-repression thesis, a gold allocation playing its dual role as geopolitical hedge and monetary-stress diversifier, and a quality equity stake tilted toward the AI capex cycle. Together, the book expresses a defensive but opportunistic posture, with the heavy cash weighting giving it the flexibility to respond when the macro picture firms up.
Cash 70.0%Inflation-linked 10.0%Equity 5.0%Gold & metals 5.0%
| Name | Weight | Thesis |
|---|
| Cash · 70.0% |
| Money Market | 70.0% | money-market / cash |
| Inflation-linked · 10.0% |
| SCHP | 4.9% | inflation-linked Treasuries |
| VTIP | 2.9% | inflation-linked Treasuries |
| LTPZ | 2.2% | inflation-linked Treasuries |
| Gold & metals · 5.0% |
| IAU | 3.0% | gold / precious-metals |
| GDX | 1.1% | gold / precious-metals |
| WPM | 0.4% | gold / precious-metals |
| FNV | 0.4% | gold / precious-metals |
| SLV | 0.1% | gold / precious-metals |
| Equity · 5.0% |
| QUAL | 2.6% | global quality equity |
| PHAT | 0.8% | global quality equity |
| TER | 0.6% | global quality equity |
| NEM | 0.5% | global quality equity |
| AENT | 0.3% | global quality equity |
| TSM | 0.1% | global quality equity |
| INOD | 0.1% | global quality equity |
| IAG | 0.1% | global quality equity |
Position notes
PHAT 0.8%
Full research note
Phathom Pharmaceuticals is a clinical-stage biopharma focused on GI treatments, primarily vonoprazan.
Bull case · Bulls point to VOQUEZNA's rapid adoption among specialists, capturing roughly 45% of new-to-brand prescriptions versus traditional PPIs among the top 300 gastroenterologists in Q1 2026. With operating expenses slashed by 43% year-over-year and the sales force fully deployed, Phathom is demonstrating a clear, de-risked path to its $320 million FY26 revenue guidance and imminent profitability.
Bear case · Bears argue that Phathom's commercial success is being bought at the expense of pricing power, highlighted by management's guidance of a steep 55% gross-to-net discount for FY26. Furthermore, the complex liability stack and the looming 2027 FDA approval of a competing P-CAB (tegoprazan) threaten to commoditize the space and trigger a race-to-the-bottom in payer negotiations just as VOQUEZNA reaches scale.
Key risks• Imminent competitive pressure from a second-to-market P-CAB (tegoprazan) expected in 2027.
• High gross-to-net discounts (55%) signaling weak pricing leverage against Pharmacy Benefit Managers (PBMs).
• Complex capital structure and debt covenants creating an accounting and financing overhang.
• Small-cap illiquidity amplifying downside volatility in a macro risk-off environment.
TER 0.6%
Full research note
The dominant 30-day narrative for Teradyne (TER) centers on its explosive transformation into an AI datacenter testing powerhouse, juxtaposed against a highly stretched valuation. Following a blowout Q1 2026 where AI-related demand drove roughly 70% of its $1.28 billion in revenue, the market is hyper-focused on its new integrated test cell partnership with Tokyo Electron and its impending inclusion in the Nasdaq-100 on June 22. However, with the stock trading at a steep premium and Q2 guidance implying a sequential revenue dip, investors are weighing these structural tailwinds against the lack of a near-term margin of safety.
Bull case · Bulls point to Teradyne's indispensable role in the AI infrastructure buildout, where testing complexity for merchant GPUs, HBM, and 2.5D/3D advanced packaging is skyrocketing. The recent launch of "physical AI" applications in its robotics division (Universal Robots and MiR) at the June 2026 Automate show, alongside a manufacturing expansion with Flex, provides a secondary growth engine that is just beginning to scale and diversify the top line.
Bear case · Bears argue that the stock is priced for perfection after a massive multi-year run, trading at over 50x trailing earnings. Cautious Q2 guidance, combined with recent insider selling filings and the inherent lumpiness of hyperscaler capex cycles, suggests the near-term upside may be capped until the next wave of data center buildouts materializes to justify the multiple.
Key risks• Valuation overhang leaving zero margin of safety for execution missteps or a deceleration in AI capex.
• Potential lumpiness in hyperscaler and foundry testing equipment orders.
• Insider selling cluster dampening retail confidence at all-time highs.
• Geopolitical exposure to US-China decoupling, which could structurally crimp semiconductor equipment exports.
NEM 0.5%
Full research note
Mining company extracting gold, copper, and other metals with operational risks and long-term reserve challenges.
Bull case · Record realized gold prices (averaging ~$2.4k/oz) and sequentially falling All-In Sustaining Costs (AISC) have unlocked tremendous operating leverage for Newmont. The newly authorized $6 billion open-ended buyback program and successful divestiture execution provide a hard floor under the stock, rewarding shareholders while management optimizes its world-class Tier 1 portfolio.
Bear case · A glaring cluster of insider selling—totaling $7.5 million over the last 90 days with zero insider buys, including sales by the CFO and Group Head of Projects—suggests management sees limited near-term upside at current valuations. Additionally, any sudden geopolitical de-escalation in the Middle East could rapidly deflate gold's safe-haven premium, exposing Newmont to a sharp mean-reversion.
Key risks• Extreme insider selling cluster signaling management caution at current valuations.
• Geopolitical de-escalation (e.g., an Iran peace deal) crushing the gold price premium.
• Persistent cost inflation in specialized labor and mining consumables.
• Macro carry-trade unwind triggering broad asset liquidation across all sectors.
AENT 0.3%
Full research note
Alliance Entertainment distributes physical media, video games, and collectibles globally.
Bull case · The strongest bull case hinges on AENT's explosive 48% year-over-year growth in its collectibles segment and its ability to consistently beat analyst expectations (Q3 EPS of $0.05 beat estimates by $0.04). By integrating recent acquisitions like Endstate and leveraging exclusive partnerships with major studios (Paramount, MGM), Alliance is successfully transitioning from a legacy media distributor into a high-value, tech-enabled collectibles ecosystem.
Bear case · The bear case focuses on underlying profitability quality and cash flow generation. Despite the top-line surge, Q3 gross margins contracted by 80 basis points to 12.8% due to product mix shifts, and analysts have flagged that operating cash flows remain weak relative to the company's debt load. Furthermore, following a massive 200%+ run over the past year, the stock faces valuation overhang and mean-reversion risks if the physical media nostalgia cycle cools.
Key risks• Gross margin compression (down 80 bps in Q3) driven by shifts in product mix.
• Weak operating cash flow coverage relative to existing debt obligations.
• Valuation overhang following a massive multi-bagger rally over the trailing 12 months.
• Consumer discretionary headwinds impacting premium collectibles spending.
TSM 0.1%
Full research note
World's largest dedicated semiconductor foundry, manufacturing chips for global customers.
Bull case · AI accelerator demand from NVDA, AMD, and hyperscalers drives revenue growth well into the next decade; TSMC's pricing power and margin expansion (66.2% gross margin in Q1 2026) are durable. Analyst revisions over the last 30 days are sharply positive (net +100% up revisions, no downgrades), reflecting a consensus that is still catching up to the AI capex cycle. Decoupling pressures paradoxically benefit TSMC as both US and China build independent chip ecosystems that all depend on leading‑edge manufacturing.
Bear case · A recession or AI capex disappointment would hit TSMC's growth assumptions hard, while the stock is already extended (+27% above 200‑day MA). Geopolitical risk is acute: a Taiwan Strait escalation would disrupt over 90% of advanced chip supply; this risk is not just a tail but an inherent feature of the concentration. US‑China decoupling could force TSMC to lose Chinese market share or require prohibitively expensive geographic diversification.
Key risks• Taiwan Strait military escalation disrupting global semiconductor supply
• AI capex cycle peaking and monetization lag triggering a 2001‑style deep correction
• US‑China decoupling forcing TSMC to choose sides, eroding addressable market
• Insider selling cluster (VP sold $14M) signaling management caution at elevated share prices
• Current the composite macro-signal score safety gate (score 64.3) limiting deployment capacity, leaving any position exposed to macro unwind
SLV 0.1%
Full research note
The dominant 30-day narrative for the iShares Silver Trust (SLV) centers on a violent macroeconomic tug-of-war. Silver prices have crashed nearly 40% from their early-2026 peaks to approach $60 per ounce, driven by a hawkish Federal Reserve, a surging US dollar, and institutional de-risking. However, the market remains hyper-focused on the underlying structural supply deficit, which is being exacerbated by exploding industrial demand from AI data centers, high-efficiency solar photovoltaics, and electrification, creating a fundamental floor under the metal's valuation.
Bull case · The strongest bullish sentiment anchors on the unprecedented industrial demand wave from AI infrastructure and newer TOPCon solar panels, which are structurally increasing silver intensity per unit. Proponents argue that with mine production severely constrained and consecutive years of global supply deficits, the current macro-driven selloff offers a generational entry point before physical shortages force a violent repricing.
Bear case · Bears point to the immediate macroeconomic reality: a structurally higher US dollar and elevated real yields under a hawkish Fed are crushing the monetary premium of precious metals. This has triggered massive volatility and forced liquidations, with the "safe haven" narrative unwinding rapidly amid potential Middle East de-escalation, leaving silver vulnerable to further downside if industrial demand softens in a recession.
Key risks• Sustained hawkishness from the Federal Reserve driving real yields higher and accelerating ETF redemptions.
• A durable resolution to the Iran-Hormuz conflict draining the geopolitical safe-haven premium from precious metals.
• Technological substitution or "thrifting" in solar panel manufacturing reducing the silver intensity per cell.
• Intense fee competition from lower-cost physical silver ETFs eroding SLV's market share among retail investors.
INOD 0.1%
Full research note
Innodata is a critical AI data engineering enabler with explosive revenue growth (+54% YoY in Q1 2026) and improving customer diversification, positioning it as a key pick-and-shovel play in the AI adoption cycle.
Bull case · AI-driven data labeling demand accelerates, new large client wins broaden revenue base beyond current concentration, and operating leverage drives margin expansion toward management's 40%+ growth target. Strong FCF generation (FCF margin 38.7% in Q1) provides balance sheet optionality.
Bear case · Heavy insider selling ($35.8M net over 90 days, 100% sell direction) and sharply negative analyst revision momentum (net upgrade rate -100% in 30d) signal internal caution; high valuation (P/E 31.9, EV/EBITDA 20.4) leaves no room for revenue or client-diversification misses. Competitive pressure from well-funded AI data unicorns and potential AI synthetic data disruption loom.
Key risks• Extreme insider selling cluster indicating potential valuation peak and internal skepticism
• Sharply bearish analyst revision momentum contradicting retail euphoria and raising near-term earnings risk
• Customer concentration risk with top customer at 56% of revenue, exposing the business to single-client churn
• Competitive pressure from better-capitalized AI data platforms like Scale AI, which could erode pricing power
• AI disruption risk from synthetic data generation reducing the need for human-in-the-loop data engineering
IAG 0.1%
Full research note
Gold mining company operating mines in the Americas and Africa, commodity-exposed business.
Bull case · The bullish narrative centers on IAMGOLD's flawless execution at Côté Gold, which has achieved its 36,000 tonnes-per-day nameplate capacity and drove record revenues exceeding $1 billion in Q1 2026. Investors are cheering management's disciplined capital allocation, highlighted by the recent repayment of its remaining $130 million 2nd Lien Term Loan and a massive 57-million share buyback program that provides a hard floor under the stock price.
Bear case · Bears point to the fragility of the gold macro environment, warning that any Iran-US peace deal or Hormuz de-escalation could trigger a sharp pullback in bullion prices, exposing IAMGOLD's still-elevated consolidated All-In Sustaining Costs (AISC) of $1,900/oz. Furthermore, a recent cluster of insider selling—with $855K unloaded by three directors in late February—signals potential internal skepticism about the durability of the current valuation peak.
Key risks• Geopolitical de-escalation (e.g., an Iran peace deal) triggering a sudden collapse in safe-haven gold premiums.
• Sector-wide cost inflation in labor and energy compressing margins if gold prices normalize.
• Insider selling cluster by directors signaling a potential near-term valuation ceiling.
• Execution risks related to the upcoming Côté Gold conveyor belt replacement and phase-out of the temporary crushing circuit.
Track Record
The track record is anchored to Clarke Envoy's first issue (June 14, 2026) — it counts only the model's recommendations published since launch, not any pre-launch history. The model has published 140 recommendations since then, and none has yet reached a scoring horizon, so no hit-rate or alpha figure is reported.
Outcomes are scored only once realized, at fixed horizons: one-week results begin maturing around June 21, 2026, four-week around July 12, 2026, and three-month around September 13, 2026. A one- or two-day return is market noise rather than evidence of skill, so the figures here fill in as positions reach each horizon — every recommendation logged before its outcome and counted, never cherry-picked. This is a hypothetical, aggregate model record, not any individual's account; past performance does not guarantee future results.
Positions, conflicts & disclosures
DISCLAIMER — NOT INVESTMENT ADVICE (DECISION-LINKED)
This publication provides GENERAL and IMPERSONAL commentary and analysis on a regular schedule. The same content is provided to every subscriber. It is NOT investment advice, is NOT tailored to any individual, and does NOT account for your personal financial situation, objectives, or risk tolerance.
This post reports (1) a rules-based MODEL portfolio — target weights produced by an automated system's published rules, identical for all readers — and (2) DECISION-LINKED activity: how that affiliated automated system actually implemented, or has queued to implement, those rules in accounts belonging to the publication's operator. Model weights are not an account statement; the decision-linked positions and pending orders are REAL and belong to accounts affiliated with this publication's operator. We publish them for transparency on a fixed schedule under our Trading & Publication Policy [link] — not as a recommendation that any security or strategy is suitable for you. Because the publisher and/or operator hold or intend to establish positions in the securities discussed, a conflict of interest exists and our interests may differ from yours.
Nothing here is a recommendation to buy, sell, or hold any security for you specifically. Investing involves risk, including loss of principal. Past performance — model or actual — does not guarantee future results.
[Publisher LLC] is not a registered investment adviser and does not provide individualized investment advice. Consult a licensed professional before making any investment decision. See full disclosures, methodology, and our Trading & Publication Policy at [link].
POSITIONS DISCLOSURE: this is a hypothetical, rules-based model portfolio, not a statement of any individual's actual account; the publisher and/or author may hold positions in one or more of the securities listed.
CONFLICT OF INTEREST: because the publisher and/or author may hold listed securities, a conflict of interest exists and could benefit from price movements; the publisher receives no compensation for featuring any security, and this impersonal model illustration is not personalized investment advice or a solicitation to transact.
MICRO-CAP CAVEAT: some listed names are micro-capitalization securities held at small model weights; micro-caps carry elevated liquidity and volatility risk and are unsuitable for short-term trading — the small weights reflect that risk, and nothing here is a recommendation to scalp or rapidly trade thinly-traded securities.
Intended transactions: the affiliated automated system has open or queued target allocations in the following securities discussed here: AENT, FNV, GDX, IAG, IAU, INOD, LTPZ, NEM, PHAT, QUAL, SCHP, SLV, TER, TSM, VTIP, WPM. These are real pending orders or model target weights in accounts belonging to the publication's operator, disclosed for transparency under our Trading & Publication Policy [link] — not a recommendation, and our interests may differ from yours.
